Koski Comments on Prospects for Prescription Drug Legislation
April 26, 2018
Pharmaceutical Technology
Partner Katy Koski was quoted in a Pharmaceutical Technology article, “CREATES Act Dropped But May Still See Progress,” about the chances that legislation aimed at lowering the costs of prescription drugs will be taken up by Congress this year.
The legislation, formally known as the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, would prevent companies making branded drugs from refusing to sell samples to firms producing lower-cost generic and biosimilar versions, who need access to branded drugs to conduct the comparative testing required to get their own versions approved.
Koski said the focus on the sample-access issue has increased significantly with the introduction of biosimilars, whose manufacturers need to buy multiple batches of branded drugs from various manufacturing lots.
The legislation, formally known as the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, would prevent companies making branded drugs from refusing to sell samples to firms producing lower-cost generic and biosimilar versions, who need access to branded drugs to conduct the comparative testing required to get their own versions approved.
Koski said the focus on the sample-access issue has increased significantly with the introduction of biosimilars, whose manufacturers need to buy multiple batches of branded drugs from various manufacturing lots.
People
Related News
July 7, 2025
In the News
Louis Lehot Assesses Deal Trends in Shifting Market
Foley & Lardner LLP partner Louis Lehot assessed dealmaking trends in the Law360 article, "PE Dealmakers Best-Suited To Cut Through M&A Challenges."
July 3, 2025
In the News
Christopher Swift Assesses CFIUS Involvement in Telecommunications Acquisition
July 3, 2025
In the News
Louis Lehot Highlights Opportunities and Challenges for M&A Market
Foley & Lardner LLP partner Louis Lehot highlighted opportunities and challenges for the M&A market in the Law360 article, "Mid-Year M&A Deal Flow Suffers Amid Global Instability."